Arthex Biotech

Arthex Biotech company information, Employees & Contact Information

Explore related pages

Related company profiles:

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary platform that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com

Company Details

Employees
28
Founded
-
Address
Catedrático Agustín Escardino, 9, Paterna,valencia 46980,spain
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Paterna, Valencia
Looking for a particular Arthex Biotech employee's phone or email?

Arthex Biotech Questions

News

ARTHEx Biotech to Participate in Upcoming Investor and Industry Events - PR Newswire

ARTHEx Biotech to Participate in Upcoming Investor and Industry Events PR Newswire

ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines - Bpifrance | Presse

ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines Bpifrance | Presse

ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference - PR Newswire

ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference PR Newswire

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) - PR Newswire

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) PR Newswire

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board - PR Newswire

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board PR Newswire

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) - PR Newswire

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) PR Newswire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant